Type 1 Diabetics using an Insulin Pump or Injections
Protocol: STUDY00002775
Full Title
Triple therapy for T1DM with insulin, semaglutide and dapagliflozin
Description
We are looking for adults with type 1 diabetes for a research study. The purpose of the study is to see how well an already approved treatment for type 2 diabetes works for people with type 1 diabetes.

You will be in this study for just over a year (55 weeks). During that time, you will have 16 study visits that will last from 45-60 mins (most visits) to 5 hours (a few visits). You will take either your current diabetes treatment or the study drug. You will also complete urine tests, blood draws, and questionnaires. Study visits will take place at 1000 Youngs Rd.,Williamsville, NY 14221.

Participants will be compensated.

Technical Description

This will be an interventional project to study the glycemic effect of the addition of a GLP-1 RA (semaglutide) and an SGLT-2 inhibitor (dapagliflozin) as adjunct therapies to insulin treatment in adult type 1 diabetes patients
Compensation: Yes
?
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Eligibility
Adults ages 18+.
Diagnosed with Type 1 diabetes.
Currently using an insulin pump or multiple daily injections of insulin.
Age Group: Adults
Principal Investigator: PARESH DANDONA
ClinicalTrials.gov: Open Study
Contact(s)
HUSAM GHANIM
ghanim@buffalo.edu
+1 716-881-8924
Want to Learn More?
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.